Personal Continuous Glucose Monitoring Use Among Adults with Type 2 Diabetes: Clinical Efficacy and Economic Impacts-Reference-Cited by-同舟云学术

Personal Continuous Glucose Monitoring Use Among Adults with Type 2 Diabetes: Clinical Efficacy and Economic Impacts

Published:2021-11 Issue:11 Volume:21 Page:
ISSN:1534-4827
Container-title:Current Diabetes Reports
language:en
Short-container-title:Curr Diab Rep

Author:

Oser Tamara K.^ORCID,Litchman Michelle L.^ORCID,Allen Nancy A.^ORCID,Kwan Bethany M.^ORCID,Fisher Lawrence^ORCID,Jortberg Bonnie T.^ORCID,Polonsky William H.^ORCID,Oser Sean M.^ORCID

Publisher

Springer Science and Business Media LLC

Subject

Endocrinology, Diabetes and Metabolism,Internal Medicine

Link

https://link.springer.com/content/pdf/10.1007/s11892-021-01408-1.pdf

Reference36 articles.

1. •• American Diabetes Association. Diabetes technology: standards of medical care in diabetes—2021. Diabetes Care. 2021;44(Suppl 1):S85–99. https://doi.org/10.2337/dc21-S007. The most current (2021) ADA Standards regarding technology use in diabetes, including CGM, and thorough consideration of evidence.

2. American Diabetes Association. Diabetes technology: standards of medical care in diabetes—2020. Diabetes Care. 2020;43(Suppl 1):S77–88. https://doi.org/10.2337/dc20-S007.

3. •• Garber AJ, Handelsman Y, Grunberger G, Einhorn D, Abramson MJ, Barzillay JI, Blonde L, Bush MA, DeFronzo RA, Garber JR, Garvey WT, Hirsch IB, Jellinger JS, McGill JB, Mechanick JI, Perreault L, Rosenblit PD, Samson S, Umpierrez GE. Consensus statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the comprehensive type 2 diabetes management algorithm—2020 executive summary. Endocr Pract. 2020;26(1):107–39. https://doi.org/10.4158/CS-2019-0472. The most current (2020) AACE/ACE statement on type 2 diabetes management, including preferred use of CGM over SMBG and reasons for this preference.

4. • Beck RW, Riddlesworth TD, Ruedy K, Ahmann A, Haller S, Kruger D, McGill JB, Polonsky W, Price D, Aronoff S, Aronson R. Continuous glucose monitoring versus usual care in patients with type 2 diabetes receiving multiple daily insulin injections: a randomized trial. Ann Intern Med. 2017;167(6):365–74. https://doi.org/10.7326/M16-2855. RCT demonstrating greater HbA1c decrease in rtCGM than SMBG, with additional benefits in mean glucose, TIR, and TAR.

5. • Haak T, Hanaire H, Ajjan R, Hermanns N, Riveline JP, Rayman G. Flash glucose-sensing technology as a replacement for blood glucose monitoring for the management of insulin-treated type 2 diabetes: a multicenter, open-label randomized controlled trial. Diabetes Ther. 2017;8(1):55–73. https://doi.org/10.1007/s13300-016-0223-6. RCT demonstrating substantial decreases in hypoglycemia in adults with T2D treated with IIT.

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Effects of continuous glucose monitoring on glycaemic control in type 2 diabetes: A systematic review and network meta‐analysis of randomized controlled trials;Diabetes, Obesity and Metabolism;2023-10-12

2. Expanding the Role of Continuous Glucose Monitoring in Modern Diabetes Care Beyond Type 1 Disease;Diabetes Therapy;2023-06-16

3. Rates and Correlates of Uptake of Continuous Glucose Monitors Among Adults with Type 2 Diabetes in Primary Care and Endocrinology Settings;Journal of General Internal Medicine;2023-05-30

4. Use of Personal Continuous Glucose Monitoring (CGM) with Support in People with Type 1 and 2 Diabetes Treated with Insulin in the Outpatient Clinic: A Single-Center Retrospective Cohort Study;Clinical Diabetology;2023-04-28

5. A Team-Based Training for Continuous Glucose Monitoring in Diabetes Care: Mixed Methods Pilot Implementation Study in Primary Care Practices;JMIR Formative Research;2023-04-24